ANIP
ANIP
Positions held
Your positionsANIP isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | — | Enterprise value | — | Trailing P/E | — | Forward P/E | — |
| PEG | — | Price / book | — | Beta | — | Dividend yield | — |
| Revenue growth | — | Earnings growth | — | Gross margin | — | Operating margin | — |
| Profit margin | — | ROE | — | ROA | — | Debt / equity | — |
| Current ratio | — | Free cash flow | — | Analyst recommendation | — | Mean target | — |
| 52w high | — | 52w low | — |
Quarterly
No data yet.
Yearly (6y)
No data yet.
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-07 · Did FDA Approval of Generic Everolimus Suspension Just Shift ANI Pharmaceuticals' (ANIP) Investment Narrative?
2026-10-06 · 1 Safe-and-Steady Stock with Competitive Advantages and 2 We Turn Down
2026-10-01 · 1 Small-Cap Stock for Long-Term Investors and 2 We Ignore
2026-09-29 · 3 Profitable Stocks Worth Investigating
2026-09-28 · Implied Volatility Surging for ANI Pharmaceuticals Stock Options
2026-09-23 · Ocular Therapeutix and ANI Pharmaceuticals Stocks Trade Down, What You Need To Know
2026-09-23 · Sector Update: Healthcare Stocks Mixed Premarket Wednesday
2026-09-23 · ANI Pharmaceuticals Wins FDA Approval for Generic Everolimus Tablets
2026-09-23 · ANI Pharmaceuticals Announces the FDA Approval of Everolimus Tablets for Oral Suspension
2026-09-23 · Oppenheimer Initiates ANI Pharmaceuticals at Perform With $85 Price Target
2026-09-18 · 2 Cash-Producing Stocks to Target This Week and 1 We Avoid
Price (daily)
Full chart · RSI · MACD · patterns